Targeted protein degradation Market Outlook 2026–2036: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines targeted protein degradation, a class of medicines that remove a disease causing protein by directing it to the cell disposal machinery instead of blocking its activity. It tests how fast PROTAC and molecular glue degraders move from the first approval into later lines, new cancers and non-cancer diseases, and which participants capture value among developers, large pharmaceutical firms and suppliers.

The first approval has arrived. In May 2026 the FDA approved VEPPANU (vepdegestrant), from Arvinas and Pfizer, for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer after endocrine therapy, ahead of its June 5 decision date. In the Phase 3 VERITAC-2 trial, median progression-free survival in the ESR1-mutated group of 270 patients was 5.0 months against 2.1 months for fulvestrant, a hazard ratio of 0.57 (95% confidence interval 0.42–0.77). The conclusion is that a PROTAC can meet a registrational standard, although the benefit is confined to a mutation defined group and overall survival data are immature.

Commercial structure is still being set. Arvinas and Pfizer said in September 2025 that they would out-license commercialization to a third party, Arvinas cut a further 15% of staff and reaffirmed cash into the second half of 2028, and on the day of approval the partner had not been named. The conclusion is that the first PROTAC reaches the market with its owners seeking a commercial partner, which shows that the cost of launch weighs on small developers.

Large firms continue to buy into the class. AbbVie agreed in January 2025 to a deal worth up to USD 1.64 billion for options on molecular glue degraders from Neomorph, and reported deals include Gilead with LEO Pharma at USD 1.7 billion and Eli Lilly with Magnet Biomedicine at USD 1.25 billion. The conclusion is that molecular glues and immune disease targets are drawing licensing value ahead of clinical proof.

The brief treats targeted protein degradation as an accelerating category with a ten year horizon to 2036. It identifies which diseases, regions and operators scale first and what each means for developers, large pharmaceutical firms and suppliers.

It is a focused 106-page decision brief for biopharma firms and investors. It presents an indicative trajectory rather than a segmented market model. Its purpose is to identify which diseases scale first and who captures value.

A PROTAC is a two part molecule that binds a target protein on one end and an E3 ubiquitin ligase on the other, which marks the protein for destruction. Vepdegestrant targets the estrogen receptor.

Molecular glues are smaller molecules that bring a target and a ligase together, and they offer better drug-like properties for oral dosing.

Reported programmes target the androgen receptor, BTK, BCL6, KRAS G12D, LRRK2, STAT6, VAV1 and ALK.

Uses are cancer today, with immune and neurological diseases under study, each under small molecule drug regulation.

The limits are large molecular size and oral absorption, the small number of E3 ligases used, resistance, and competition from inhibitors and other modalities. The decade turns on whether degraders show a benefit over inhibitors that justifies their complexity.

The targeted protein degradation market, covering sales of approved protein degraders, related licensing and collaboration revenue, and related discovery and manufacturing services, is valued at USD 0.2–0.4 billion in 2026 and is projected to reach USD 5.79–11.57 billion by 2036, at a CAGR of 40%.

The 2026 base rests on the first sales of an approved PROTAC, licensing and collaboration income, and discovery and manufacturing services. Growth then follows further PROTAC approvals, molecular glue registrations and degraders for immune and neurological disease.

The forecast is sensitive to pivotal trial results, commercial partnering, oral exposure and competition from inhibitors. Regionally, North America leads on companies, deals and trials, Europe on academic research, and Asia-Pacific on fast following developers.

The base case assumes Phase 3 readouts for further PROTACs around 2028 and 2029 and the first molecular glue registrations in the early 2030s, giving the inflection in 2032. An accelerated case assumes strong sales of the first PROTAC and early registrations for immune targets, bringing the inflection to 2030 and lifting the 2036 value to the top of the range. A delayed case assumes weak launch uptake and trial failures, holding growth at the bottom of the range.

Growth drivers

• Patients who progress on inhibitors.
• First approved oral PROTAC in breast cancer.
• Late-stage trials in prostate cancer and B cell malignancies.
• Large pharmaceutical investment in degraders.

Enablers

• Venture funding and financing rounds.
• Biopharma licensing and partnerships.
• Public research funding.
• Chemistry and discovery platforms.

Restraints and barriers

• Large molecular size and oral absorption.
• Limited number of E3 ligases used.
• Competition from inhibitors and other modalities.
• Cost and complexity of development.

The direction of targeted protein degradation is set by the need to reach targets that inhibitors cannot, regulation, new targets and E3 ligases, biopharma dealmaking and partnering, and development cost.

The key participants in targeted protein degradation include Arvinas, Inc., Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG, AbbVie Inc., Monte Rosa Therapeutics, Inc., Neomorph, Inc., Kymera Therapeutics, Inc., C4 Therapeutics, Inc., Nurix Therapeutics, Inc., BeOne Medicines Ltd., Gilead Sciences, Inc., LEO Pharma A/S, Eli Lilly and Company, Magnet Biomedicine, Inc., Orum Therapeutics, Inc., TRIANA Biomedicines, Inc., Sanofi, F. Hoffmann-La Roche Ltd, AstraZeneca PLC, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Lonza Group Ltd, Thermo Fisher Scientific Inc., Charles River Laboratories International, Inc., Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, American Society of Clinical Oncology, American Association for Cancer Research, European Society for Medical Oncology, American Society of Hematology, U.S. Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, Pharmaceuticals and Medical Devices Agency, National Medical Products Administration, International Council for Harmonisation and United States Pharmacopeia.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as targeted protein degradation matures.

Arvinas and Pfizer lead on the first approval, Bristol-Myers Squibb and BeOne Medicines hold later stage PROTACs, Kymera, C4, Nurix and Monte Rosa lead platform developers, and AbbVie, Novartis, Gilead and Eli Lilly shape the class through licensing, while chemistry suppliers, cancer centres, regulators and standards bodies influence the speed of adoption. Competitive intensity is moderate in 2026 because one product is approved and most are early, and it rises as further Phase 3 data arrive.

Where value migrates.

In 2026 value sits with the sponsors of the first approved PROTAC and the platform developers that license programmes to large firms. By 2032 it moves toward companies with several approved degraders, because payers and prescribers choose products with proven benefit over inhibitors. By 2036 it settles in integrated degrader discovery and development platforms and in suppliers with scaled chemistry capacity. Margins hold for products with a clear benefit over inhibitors and narrow for late followers on shared targets.

The signals converge on a first approval and continued dealmaking. The FDA approved a PROTAC in May 2026 with a hazard ratio of 0.57 for progression, large firms signed licensing deals of USD 1.25 billion to USD 1.7 billion for degraders, and further PROTACs are in Phase 3. Each signal supports growth, and the first product still needs a commercial partner.

Structural limits show where progress could slow: large molecular size, the small number of E3 ligases used, competition from inhibitors and the cost of development. The brief therefore tracks four indicators: sales of the first PROTAC, Phase 3 readouts, molecular glue registrations and deal values.

Breast and prostate cancer, then B cell malignancies and other cancers, then immune and neurological disease are the expected order of development.